A Phase I Dose-Escalation Study of IMGN388 in Patients With Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 12 Sep 2013
At a glance
- Drugs IMGN 388 (Primary)
- Indications Breast cancer; Lung cancer; Malignant melanoma; Ovarian cancer; Sarcoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 22 May 2012 Actual patient number is 60 as reported by ClinicalTrials.gov.
- 22 May 2012 Planned end date changed from 1 Oct 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 22 May 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.